CSL Ltd Annual Report 2021

15 Key Performance Data Summary Some data points contained in this report have been summarised and grouped according to CSL’s key sustainability topics and provided over a three-year period. Performance Indicator More in this report (page reference) Measure 2018/19 2019/20 2020/21 Economic Contribution Operating revenue 7 US$ million 8,519 † 9,151 † 10,310 † Net profit US$ million 1,919 † 2,103 † 2,375 † Economic value generated 43 US$ million 8,552 † 9,158 † 10,314 † Economic value distributed US$ million 8,409 † 8,832 † 9,959 † Innovation R&D investment 7 US$ million 832 922 *† 1,001 † Our People Total headcount 50 Number 25,031 27,009 25,415 Total Recordable Injury Frequency Rate (TRIFR) ‡ 53 Per million hours worked for Non-CSL Plasma sites For all sites – 7.2. Methodology for reporting changed in 19/20 – please see page 53 for more. For all sites – 6.1 † . Methodology for reporting changed in 19/20 – please see page 53 for more. 1.9 † Per million hours worked for CSL Plasma 11.2 † Fatalities (including contractors) Number 0 † Employee engagement 52 Percentage 74 † 76.4 † 73.7 † Safety and Quality Regulatory audits 43 Number 440 *† 401 *† 365 † Quality audits of suppliers Number 580 *† 476 *† 481 ** Safety related recalls of finished product Number 3 *† 2 *† 3 † Community Total contribution 54 US$ million 56.0 44.6 ^ 55.2 # Product access support (subset of total community contribution) 44 US$ million 21.7 † 9.8 †^ 20.2 #† Marketing and Promotion Breaches 48 Number 0 † 2 † 0 † Environment § Energy consumption 41 Petajoules 3.39 * 3.79 3.73 Greenhouse gas emissions Metric kilotonnes 319 * 344 326 Water consumption Gigalitres 3.87 * 4.25 4.44 Waste Metric kilotonnes 61.40 * 66.75 59.02 Waste recycling rate Percentage 42 * 46 40 * Excludes CSL Behring’s operations in Wuhan, China (previously Ruide). † D ata for nominated period has received limited assurance by Ernst and Young, with Operating Revenue and Net Profit extracted from the audited financial statements. ‡ For 2018/19 Ernst & Young assured underlying data only. § See page 41 for more on reporting boundary. # A ccounting practices for Seqirus Australia product donations changed in 2020/21 to account for indirect and direct costs (versus direct only for prior years). ^ D ata has been restated upwards to include Seqirus contribution to the World Health Organization which was not disclosed in 2019/20’s Annual Report due to a timing discrepancy. ** Q uality audits of suppliers undertaken by CSL’s Wuhan, China (previously Ruide) are not included in the reported totals. Processes are yet to be integrated. Data has received limited assurance by Ernst & Young. Reporting Boundary Our disclosure covers the businesses and operations over which we exercise direct control and incorporates CSL Limited, CSL Behring (including CSL Plasma), Seqirus, and global research and development (R&D), including Calimmune which was acquired in 2017. This includes our seven manufacturing facilities in Australia, Europe, the UK and the US as well as R&D, sales and marketing, distribution and administration activities co-located with these facilities. Other R&D activities, sales and marketing, distribution and administrative activities occurring away from our manufacturing facilities are also covered by this report, including the full network of donation centres, laboratories and administration offices operated by CSL Plasma. For some of our operations we continue to work towards fully integrating systems and processes for the acquired operations in Wuhan, China, (previously Ruide). Unless otherwise indicated, data for Wuhan, China has been included. CSL’s acquisition of Vitaeris, announced in June 2020 has been excluded. CSL Limited Annual Report 2020/21 157